Rockefeller Capital Management L.P. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Rockefeller Capital Management L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	SELL	$144.95 - $152.29 $3,768 - $3,959	-26 Reduced 55.32%	21 $3,000
Q2 2022 Aug 12, 2022	SELL	$83.14 - $145.99 $665 - $1,167	-8 Reduced 14.55%	47 $6,000
Q1 2022 May 13, 2022	SELL	$110.08 - $142.92 $10,347 - $13,434	-94 Reduced 63.09%	55 $6,000
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $14,859 - $22,123	149 New	149 $20,000
Q3 2021 Nov 12, 2021	SELL	$98.85 - $138.91 $1,285 - $1,805	-13 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$65.78 - $105.02 $855 - $1,365	13 New	13 $1,000
Q1 2021 May 11, 2021	SELL	$64.07 - $91.75 $90,530 - $129,642	-1,413 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$65.07 - $98.24 $136,386 - $205,911	-2,096 Reduced 59.73%	1,413 $121,000
Q3 2020 Nov 13, 2020	BUY	$59.04 - $77.95 $44,693 - $59,008	757 Added 27.51%	3,509 $228,000
Q2 2020 Aug 12, 2020	SELL	$29.01 - $74.23 $64,750 - $165,681	-2,232 Reduced 44.78%	2,752 $201,000
Q4 2019 Feb 07, 2020	BUY	$40.86 - $57.65 $203,646 - $287,327	4,984 New	4,984 $271,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.